Slideshow

Diabetes News Roundup: September 2018

Author(s):

Mark L. Fuerst

Three new studies in diabetes research highlight the importance of whole grains and gluten in T2DM and T1DM risk. 

Related Videos
Evaluating the Medtronic 780G System in Type 2 Diabetes | Image Credit: HCPLive
Understanding Omnipod 5 AID and SECURE-T2D | Image Credit: HCPLive
Alice Cheng, MD: Exploring the Link Between Diabetes and Dementia | Image Credit: LinkedIn
Jennifer B. Green, MD: Implementation of Evidence-Based Therapies for T2D | Image Credit: Duke University
Ralph A. DeFronzo, MD: Noxious Nine and Mifepristone for Hypercortisolism in T2D | Image Credit: LinkedIn
Viet Le, DMSc, PA-C | Credit: APAC
Diabetes Dialogue: Tirzepatide’s Long-Term Obesity Data | Image Credit: HCPLive
Diabetes Dialogue: Latest Updates on Semaglutide Shortage, Data | Image Credit: HCPLive
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
Related Content
The HCPFive: Top News for Healthcare Providers from the Week of 02/16 | Image Credit: HCPLive
February 22nd 2025

The HCPFive: Top News for Healthcare Providers from the Week of 02/16

HCPLive Editorial Staff
Default thumbnail for Diabetes Dialogue, featuring podcast logo and headshots of hosts.
February 15th 2025

Diabetes Dialogue: Omnipod 5 and Medtronic 780G for Type 2 Diabetes

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
Sotagliflozin Cuts MACE Risk By 23% in Patients with Type 2 Diabetes, CKD | Image Credit: Mount Sinai
February 18th 2025

Sotagliflozin Cuts MACE Risk By 23% in Patients with Type 2 Diabetes, CKD

Connor Iapoce
Medical Ethics Unpacked: GLP-1 Allocation
February 5th 2025

Medical Ethics Unpacked: GLP-1 Allocation and Challenges of Equitable Access

Steve Levine, MD Dominic Sisti, PhD
CELZ-201 Cuts Insulin Dependency at 1 Year in Patients with Type 2 Diabetes | Image Credit: LinkedIn
February 11th 2025

CELZ-201 Cuts Insulin Dependency at 1 Year in Patients with Type 2 Diabetes

Connor Iapoce
Novo Nordisk | Credit: Novo Nordisk
February 5th 2025

Monlunabant Misses Primary Endpoint in Phase 2 Diabetic Kidney Disease Trial

Abigail Brooks, MA
© 2025 MJH Life Sciences

All rights reserved.